|
1
|
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
|
Hepatology
|
2009
|
1.27
|
|
2
|
Inhibiting TGF-β signaling in hepatocellular carcinoma.
|
Biochim Biophys Acta
|
2010
|
1.20
|
|
3
|
Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
|
PLoS One
|
2013
|
1.06
|
|
4
|
Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells.
|
Oncogene
|
2004
|
1.04
|
|
5
|
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.
|
BMC Cancer
|
2014
|
0.94
|
|
6
|
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.
|
Clin Dev Immunol
|
2011
|
0.89
|
|
7
|
Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC.
|
Mol Cancer
|
2009
|
0.88
|
|
8
|
Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
|
Anticancer Res
|
2013
|
0.88
|
|
9
|
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
|
Cancer Chemother Pharmacol
|
2010
|
0.84
|
|
10
|
PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.
|
Int J Cancer
|
2012
|
0.83
|
|
11
|
The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer.
|
Cancer Causes Control
|
2014
|
0.82
|
|
12
|
Frictional purpuric eruption associated with angiotensin II receptor blockers.
|
Dermatol Ther
|
2013
|
0.80
|
|
13
|
Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.
|
Cancer Genomics Proteomics
|
2012
|
0.79
|
|
14
|
Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide.
|
Eur J Dermatol
|
2012
|
0.78
|
|
15
|
Reply: To PMID 21674557.
|
Hepatology
|
2013
|
0.75
|